Targeting PLK1 overcomes T-DM1 resistance via CDK1-dependent phosphorylation and inactivation of Bcl-2/xL in HER2-positive breast cancer

Tackling intra- and inter-tumor heterogeneity to combat triple negative breast cancer

(2017) Ritu Aneja   Frontiers in Bioscience-Landmark

Cancer statistics, 2016

(2016) Rebecca L. Siegel et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Functional Genomic Landscape of Human Breast Cancer Drivers, Vulnerabilities, and Resistance

(2016) Richard Marcotte et al.   CELL

Polo-like Kinase-1 Regulates Myc Stabilization and Activates a Feedforward Circuit Promoting Tumor Cell Survival

(2016) Daibiao Xiao et al.   MOLECULAR CELL

The ErbB2ΔEx16 splice variant is a major oncogenic driver in breast cancer that promotes a pro-metastatic tumor microenvironment

(2016) J Turpin et al.   ONCOGENE

Mechanisms of resistance and sensitivity to anti-HER2 therapies in HER2+ breast cancer

(2016) Debora de Melo Gagliato et al.   Oncotarget

Activation of the endomitotic spindle assembly checkpoint and thrombocytopenia in Plk1-deficient mice

(2015) M. Trakala et al.   BLOOD

Phase III randomized trial of volasertib combined with low-dose cytarabine (LDAC) versus placebo plus LDAC in patients aged ≥65 years with previously untreated, acute myeloid leukemia (AML) ineligible for intensive remission induction therapy

(2015) Daniel J. DeAngelo et al.   Clinical Lymphoma Myeloma & Leukemia

Polo-Like Kinase 1 as a Potential Therapeutic Target for Osteosarcoma

(2015) Li Cheng et al.   CURRENT PHARMACEUTICAL DESIGN

Targeting HER2 with T-DM1, an Antibody Cytotoxic Drug Conjugate, is Effective in HER2 Over Expressing Bladder Cancer

(2015) Tetsutaro Hayashi et al.   JOURNAL OF UROLOGY

Targeting Polo-Like Kinases: A Promising Therapeutic Approach for Cancer Treatment

(2015) Xiaoqi Liu   Translational Oncology

Randomized, phase 2 trial of low-dose cytarabine with or without volasertib in AML patients not suitable for induction therapy

(2014) H. Dohner et al.   BLOOD

Trastuzumab emtansine: mechanisms of action and drug resistance

(2014) Mark Barok et al.   BREAST CANCER RESEARCH

T-DM1, a novel antibody-drug conjugate, is highly effective against uterine and ovarian carcinosarcomas overexpressing HER2

(2014) Roberta Nicoletti et al.   CLINICAL & EXPERIMENTAL METASTASIS

Subtyping of breast cancer using reverse phase protein arrays

(2014) Johanna Sonntag et al.   Expert Review of Proteomics

Polo-like kinases: structural variations lead to multiple functions

(2014) Sihem Zitouni et al.   NATURE REVIEWS MOLECULAR CELL BIOLOGY

A pan-cancer proteomic perspective on The Cancer Genome Atlas

(2014) Rehan Akbani et al.   Nature Communications

Current clinical trials with polo-like kinase 1 inhibitors in solid tumors

(2013) Hyungshin Yim   ANTI-CANCER DRUGS

Modeling precision treatment of breast cancer

(2013) Anneleen Daemen et al.   GENOME BIOLOGY

Polo-like Kinase 1: A Potential Therapeutic Option in Combination with Conventional Chemotherapy for the Management of Patients with Triple-Negative Breast Cancer

(2012) V. Maire et al.   CANCER RESEARCH

Concomitant Targeting of Tumor Cells and Induction of T-cell Response Synergizes to Effectively Inhibit Trastuzumab-Resistant Breast Cancer

(2012) Q. Wang et al.   CANCER RESEARCH

Killing cells by targeting mitosis

(2012) E Manchado et al.   CELL DEATH AND DIFFERENTIATION

Differential gene and transcript expression analysis of RNA-seq experiments with TopHat and Cufflinks

(2012) Cole Trapnell et al.   Nature Protocols

Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer

(2012) Sunil Verma et al.   NEW ENGLAND JOURNAL OF MEDICINE

Strong EGFR signaling in cell line models of ERBB2-amplified breast cancer attenuates response towards ERBB2-targeting drugs

(2012) F Henjes et al.   Oncogenesis

Polo-Box Domain Inhibitor Poloxin Activates the Spindle Assembly Checkpoint and Inhibits Tumor Growth in Vivo

(2011) Juping Yuan et al.   AMERICAN JOURNAL OF PATHOLOGY

TP53 genomics predict higher clinical and pathologic tumor response in operable early-stage breast cancer treated with docetaxel-capecitabine ± trastuzumab

(2011) Stefan Glück et al.   BREAST CANCER RESEARCH AND TREATMENT

Pharmacogenomics

(2011) Dan M. Roden et al.   CIRCULATION

Trastuzumab Emtansine: A Unique Antibody-Drug Conjugate in Development for Human Epidermal Growth Factor Receptor 2-Positive Cancer

(2011) P. M. LoRusso et al.   CLINICAL CANCER RESEARCH

HER2-amplified breast cancer: mechanisms of trastuzumab resistance and novel targeted therapies

(2011) Devika Gajria et al.   Expert Review of Anticancer Therapy

Prolonged mitotic arrest triggers partial activation of apoptosis, resulting in DNA damage and p53 induction

(2011) James D. Orth et al.   MOLECULAR BIOLOGY OF THE CELL

Multiple molecular mechanisms underlying trastuzumab and lapatinib resistance in JIMT-1 breast cancer cells

(2010) Katri Köninki et al.   CANCER LETTERS

Polo-like Kinase 1 (Plk1) as a Novel Drug Target in Chronic Myeloid Leukemia: Overriding Imatinib Resistance with the Plk1 Inhibitor BI 2536

(2010) K. V. Gleixner et al.   CANCER RESEARCH

Targeting Polo-like Kinase in Cancer Therapy

(2010) Y. Degenhardt et al.   CLINICAL CANCER RESEARCH

Maytansinoid-Antibody Conjugates Induce Mitotic Arrest by Suppressing Microtubule Dynamic Instability

(2010) E. Oroudjev et al.   MOLECULAR CANCER THERAPEUTICS

Mitochondria and cell death: outer membrane permeabilization and beyond

(2010) Stephen W. G. Tait et al.   NATURE REVIEWS MOLECULAR CELL BIOLOGY

Modeling ERBB receptor-regulated G1/S transition to find novel targets for de novo trastuzumab resistance

(2009) Özgür Sahin et al.   BMC Systems Biology

Understanding the Mechanisms Behind Trastuzumab Therapy for Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer

(2009) Neil L. Spector et al.   JOURNAL OF CLINICAL ONCOLOGY

Antitumor efficacy of IPI-504, a selective heat shock protein 90 inhibitor against human epidermal growth factor receptor 2-positive human xenograft models as a single agent and in combination with trastuzumab or lapatinib

(2009) C. C. Leow et al.   MOLECULAR CANCER THERAPEUTICS

ABT-263: A Potent and Orally Bioavailable Bcl-2 Family Inhibitor

(2008) C. Tse et al.   CANCER RESEARCH

Targeting HER2-Positive Breast Cancer with Trastuzumab-DM1, an Antibody-Cytotoxic Drug Conjugate

(2008) G. D. Lewis Phillips et al.   CANCER RESEARCH